Add to a list

Inactive Instrument

Depomed Inc Stock Nasdaq

US2499081048

Last Transcript: Depomed Inc

Assertio Holdings, Inc., Q4 2025 Earnings Call, Mar 16, 2026

Mar. 16

More transcripts

Analysts' recommendations: Depomed Inc

Apr. 09	HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35	MT
24-07-03	HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target	MT
24-03-12	Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating	MT
23-05-10	BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating	MT
23-05-10	Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating	MT

More recommendations

Managers and Directors: Depomed Inc

Director	Title	Age	Since
Ravi Yadavar BRD	Director/Board Member	26	2026-06-15
Punit Patel BRD	Director/Board Member	-	2026-06-15

More insiders

Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâ€™s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Market Cap	152M 133M 124M 114M 214M 14.66B 218M 1.48B 577M 7.19B 570M 558M 24.88B	P/E 2027 *	-	P/E 2028 *	-
Enterprise Value	129M 113M 105M 96.66M 181M 12.43B 185M 1.26B 489M 6.09B 483M 473M 21.09B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	98.57%	Yield 2027 *	-	Yield 2028 *	-

Jun. 16	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
Jun. 16	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI
Jun. 15	Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index	CI
Jun. 15	Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index	CI
Jun. 15	Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc..	CI
May. 13	Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..	CI
May. 13	Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million.	CI
May. 13	Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash	RE
May. 13	Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC	MT
May. 13	Zydus to Acquire Assertio for $166.4 Million	DJ
May. 08	Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 08	Assertio and Garda mutually agree to delay launch of tender offer	RE
May. 05	Assertio and Garda mutually agree to postpone commencement of tender offer	RE

Jun. 16	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
May. 19	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
May. 13	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
May. 08	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
May. 05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEPOMED INC	-9.45%	+3.54%	-	-	152M
ELI LILLY AND COMPANY	+1.97%	+2.53%	+52.73%	+156.66%	1,037B
JOHNSON & JOHNSON	+1.42%	+4.96%	+54.39%	+52.34%	615B
ABBVIE INC.	+1.43%	+5.25%	+37.31%	+78.74%	448B
ROCHE HOLDING AG	+5.14%	+5.84%	+37.54%	+27.28%	326B
NOVARTIS AG	+1.85%	+4.64%	+38.53%	+39.87%	293B
ASTRAZENECA PLC	-0.11%	+0.97%	+22.57%	+17.81%	264B
NOVO NORDISK A/S	+0.25%	-3.10%	-24.44%	-42.25%	216B
AMGEN INC.	+1.49%	+3.68%	+21.53%	+58.21%	198B
GILEAD SCIENCES, INC.	+0.40%	-0.64%	+18.78%	+62.28%	162B
Average	-0.19%	+1.12%	+28.77%	+50.10%	395.27B
Weighted average by Cap.	+0.53%	+1.47%	+38.33%	+75.23%

	2027 *	2028 *
Net sales	-	-
Net income	400K 352K 327K 300K 563K 38.63M 574K 3.9M 1.52M 18.93M 1.5M 1.47M 65.53M	-
Net Debt	-	-

Depomed Inc Stock Nasdaq

Stocks

US2499081048

Pharmaceuticals

Valuation: Depomed Inc

Latest news : Depomed Inc

Last Transcript: Depomed Inc

Analysts' recommendations: Depomed Inc

Press Releases: Depomed Inc

Quotes and Performance

Managers and Directors: Depomed Inc

Other Pharmaceuticals

Financials

Company Profile